PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21364010-0	2011	hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.	Imatinib Mesylate	15-23	telomerase reverse transcriptase	Homo sapiens	0-5	
21364010-5	2011	We showed that sensitivity to imatinib can be partly restored in imatinib-resistant cells by targeting telomerase expression, either by the introduction of a dominant-negative form of the catalytic protein subunit of the telomerase (hTERT) or by the treatment with all-trans-retinoic acid, a clinically used drug.	Imatinib Mesylate	30-38	telomerase reverse transcriptase	Homo sapiens	233-238	
21364010-6	2011	Furthermore, we showed that hTERT overexpression favors the development of imatinib resistance through both its antiapoptotic and telomere maintenance functions.	Imatinib Mesylate	75-83	telomerase reverse transcriptase	Homo sapiens	28-33